priors.science/reviews/perioperative-immunotherapy-solid-tumours

Perioperative Immunotherapy Solid Tumours

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

17claims tracked
159primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
5 Established · 9 Likely · 3 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableAdjuvant nivolumab vs ipilimumab in melanomaMelanomaEstablished88%13
StableAdjuvant pembrolizumab in stage III melanomaMelanomaEstablished88%14
StableKEYNOTE-522 pathological complete response and event-free survival in triple-negative breast cancerTnbcEstablished88%8
StablePerioperative nivolumab event-free survival in non-small cell lung cancerNsclcEstablished87%12
StablePerioperative pembrolizumab event-free and overall survival in non-small cell lung cancerNsclcEstablished86%13
StableMicrosatellite instability-high colon cancer immune checkpoint inhibitor surrogate biomarkerMsi ColonLikely78%10
StableNeoadjuvant dual immune checkpoint inhibitor pathological complete response in microsatellite instability-high colon cancerMsi ColonLikely77%10
StableAdjuvant pembrolizumab in stage IIB-C melanomaMelanomaLikely76%17
StableAdjuvant pembrolizumab disease-free and overall survival in renal cell carcinomaRCCLikely76%8
StablePerioperative immune checkpoint inhibitor expansion in muscle-invasive bladder cancerBladderLikely75%10
StableAdjuvant nivolumab disease-free survival in bladder cancerBladderLikely74%10
StablePathological complete response as surrogate for non-small cell lung cancer immune checkpoint inhibitor therapyNsclcLikely73%8
StablePathological complete response surrogate for triple-negative breast cancer immune checkpoint inhibitor therapyTnbcLikely72%8
StableAdjuvant pembrolizumab disease-free survival in non-small cell lung cancerNsclcLikely70%11
StableAdjuvant immune checkpoint inhibitor benefit is agent-specific in renal cell carcinomaRCCUncertain63%9
StableAdjuvant nivolumab benefit independent of PD-L1 statusBladderUncertain57%11
StableImmune checkpoint inhibitor neoadjuvant benefit inconsistent in triple-negative breast cancerTnbcUncertain54%11
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic